Seton Hall University

eRepository @ Seton Hall
Student Works
2022

Reclassifying Cannabis as a Schedule III Drug
RJ Prifitera

Follow this and additional works at: https://scholarship.shu.edu/student_scholarship
Part of the Law Commons

Seton Hall Law

Reclassifying Cannabis as a Schedule III Drug
This essay explores the statutory framework of the federal Controlled Substances Act
(CSA) and its classification of cannabis as a Schedule I drug. It is impossible to discuss the
federal prohibition cannabis without discussing its United States drug control history. Cannabis
did not become an alleged social problem until around 1910, when reports emerged that Mexican
immigrants and African Americans in Texas and New Orleans, Louisiana, respectively, were
using the drug.1 The name “cannabis” was shifted to “marijuana” in order to associate the drug
with Mexican immigrants.2 The history of cannabis in the U.S. is tied to music, specifically jazz
musicians.3 There was a fear that the jazz musicians would use the drugs to seduce white
women.4 In the 1920s to 1930s the states started to outlaw cannabis. 5
Federal prohibition of cannabis starts with Harry J. Anslinger, who was the first head of
the Federal Bureau of Narcotics (FBN). Anslinger was a racist that associated “dangerous” drug
use with minoritized Americans.6 He facilitated a large disinformation campaign to advance the
narrative that cannabis caused people to go crazy. 7 Following Anslinger’s lead, government
officials ignored science and research on cannabis out of fear of the American culture becoming
“blackened.”8
FBN advocated for the Uniform Narcotic Drug Act of 1932 and facilitated the enactment
of the Marijuana Tax Act of 1937.9 These laws were the precursors to federal prohibition of
cannabis.10 FBN worked alongside the National Conference of the Commissioners on Uniform
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State Laws (NCCUSL)11 to draft the Uniform Narcotic Drug Act.12 The annual proceedings of
the Commissioners show that the Commission did not undertake a scientific study of any kind to
inform the cannabis section of the Uniform Narcotic Drug Act. 13 In their 1970 law review article,
Richard J. Bonnie and Charles H. Whitebread II, suggest that Congress was “hoodwinked” into
passing the Marijuana Tax Act by the FBN and its campaign of public hysteria surrounding
cannabis.14
Congress outlawed cannabis with the passage of the CSA in 1970 as part of the War on
Drugs.15 President Nixon, who signed the CSA into law, feared social and political movements
of the time were a threat to his presidency. 16 He created the DEA by executive order and
expanded law enforcement for crimes related to illegal drugs. 17
The CSA classifies controlled substances into one of five schedules. 18 Schedule I drugs
are banned illegal substances that cannot be used outside a federally-approved research study.19
Schedule II-V drugs have legitimate medical uses and, as such, can be prescribed by a physician
for use.20 Nixon commissioned a report, called the Shafer Report, to assess the dangerousness of
cannabis.21 The results of the report were so controversial that members of the Shafer
Commission held a televised event to discuss their findings. 22 During this event, the members of
the Commission explained there the public had been inundated with widespread cannabis
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misinformation and that they wanted to “demythologize” the drug. 23 The Commission members
reported that occasional marijuana use does not do any physical harm and may not do any
psychological harm.24 As such, the report ultimately recommended decriminalizing small
amounts of cannabis.25 Nixon and his administration, however, ignored that proposal and,
instead, doubled down on cannabis criminalization. 26 Nixon made it clear that he would continue
to thwart efforts to legalize cannabis and push for harsh penalties for cannabis possession and
use.27
This paper proceeds in six parts. Part I discusses the rescheduling process that needs to
take place in order to reschedule drugs listed in the CSA. Part II describes what criteria is used to
determine how drugs are scheduled on the Schedule I drug list in the CSA, as well as the
misplacement of cannabis on the Schedule I list. As the section details, cannabis has a low
potential for abuse; cannabis has known and accepted medical uses, and there are even FDA
approved drugs derived from cannabis; the DEA medical use factors are satisfied as applied to
cannabis; there is accepted safety for use of the drug under medical supervision. Therefore,
cannabis does not belong on Schedule I of the CSA.
Part III describes what criteria is used to determine the placement of a drug on the
Schedule III list of the CSA and why cannabis belongs on Schedule III. Part IV looks at the
Marijuana Opportunity Reinvestment and Expungement Act (MORE) and its implications for
full cannabis legalization. Part V argues that rescheduling cannabis will allow for increased
medical usage and greater opportunities for research. This section also discusses why the FDA,
as a regulatory body, is more suited to handle the rescheduling process of the CSA, rather than
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the DEA. This Article concludes arguing for removal of cannabis as a Schedule I drug as the first
step towards full legalization. This paper does not argue that cannabis should not be fully
decriminalized in time, but rather, rescheduling cannabis is the first step in the process to full
legalization.
I. The Rescheduling Process
The DEA controls the scheduling and rescheduling of drugs on the CSA schedules.28
There is, however, shared authority between the Food and Drug Administration (FDA), the
DEA, the Secretary of Health and Human Services (HHS), and the Attorney General (AG) in the
scheduling decision process.29 The process starts with either an interested outside party or the
Secretary of HHS filing a petition to reschedule the drug or substance with the AG. 30
Before the AG can reschedule any controlled substance it must request a scientific and
medical evaluation and scheduling recommendation from the Secretary. 31 The CSA requires the
consideration of eight statutory factors to determine the appropriate schedule for a substance. 32
The DEA has narrowed this analysis to five factors, and this paper will discuss those factors in
its Schedule I analysis.33 The CSA also requires the Secretary to make a scheduling
recommendation, which in turn means the FDA (on behalf of the Secretary) must, provide its

The Controlled Substances Act, U.S. DRUG ENF’T ADMIN., https://www.dea.gov/druginformation/csa#:~:text=S.C.,The%20manufacturer%20of%20a%20drug (last visited April 5, 2022).
29 Rebecca S. Eisenberg & Deborah B. Leiderman, Cannabis for Medical Use: FDA and DEA Regulation in the Hall
of Mirrors, 74 FOOD DRUG L.J., 246, 256-257 (2019).
30 John Hudak and Grace Wallack, How to reschedule marijuana, and why it’s unlikely anytime soon , B ROOKINGS.,
(Feb. 13, 2015) https://www.brookings.edu/blog/fixgov/2015/02/13/how-to-reschedule-marijuana-and-why-itsunlikely-anytime-soon/
31 Leiderman, supra note 29 at 256-258.
32 See id. There are eight statutory factors to be considered with the rescheduling of a drug: (1) Its actual or relative
potential for abuse; (2) Scientific evidence of its pharmacological effect, if known; (3) The state of current scientific
knowledge regarding the drug or other substance; (4) Its history and current pattern of abuse; (5) Th e scope,
duration, and significance of abuse; (6) What, if any, risk there is to the public health; (7) Its psychic or
physiological dependence liability; (8) Whether the substance is an immediate precursor of a substance already
controlled under this subchapter.
33 See id.
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evaluation of whether a substance has a currently accepted medical use in the United States.34
The AG will then review the FDA’s recommendations to determine if a drug should be
rescheduled .35 The AG will initiate a rulemaking proceeding for rescheduling if it finds that
there is substantial evidence that the given drug should be rescheduled.36 The FDA has recently
approved multiple drugs whose active ingredients are synthetic cannabinoids and this paper
discusses those products in the following section.
II. Cannabis as a Schedule I Drug
According to the CSA, “a drug or other substance may not be placed in any schedule
unless the findings required for such schedule are made with respect to such drug or other
substance.”37 To place a drug on Schedule I, the findings required are as follows: (1) the drug or
other substance has a high potential for abuse; (2) the drug or other substances has no currently
acceptable medical uses in treatment in the United States; (3) there is a lack of accepted safety
for use of the drug or other substance under medical supervision. This section explores why these
elements are not satisfied as applied to cannabis.
The first prong of the required findings describes a Schedule I substances as drugs that
have a “high potential for abuse.”38 There is substantial disagreement, however, whether
cannabis has a high potential for abuse. Much like the Shafer Report, the case law acknowledges
that there is mass misinformation about cannabis and its dangers. 39 Studies demonstrate that
heavy use of cannabis does not result in physical dependence on tetrahydrocannabinol (THC) 40 ,
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the chemical in cannabis responsible for psychoactive reactions.41 Scholars have observed that
marijuana is not associated with death like other drugs. 42 In fact, there has never been a recorded
death from a cannabis overdose.43 A cannabis user needs to ingest cannabis at thousands of times
the average dose in order to overdose.44 Marijuana use can cause an increase in heart rate or
blood pressure but these cardiovascular effects are unlikely to be of clinical significance. 45
The American Journal of Emergency Medicine reported that lifetime use of marijuana is
rarely associated with emergency room visits.46 For the few marijuana users that do develop
THC dependence, such dependence appears to be less severe than dependence on other drugs. 47
The World Health Organization has taken the position that the risks of marijuana are small and
unlikely to produce public health problems of the scale of other drugs like alcohol and tobacco. 48
A 2005 University of Oxford study determined that there is little evidence that long term
cannabis use causes permanent cognitive impairment. 49 Similar to this finding, researchers have
suggested that marijuana can induce acute memory-related brain inhibition, but that does not
necessarily mean that memory loss will persist after a period of abstinence. 50 Some studies
suggest that about a month of abstinence can reverse cognitive deficiencies in chronic cannabis
users.51
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43 DOUGLAS A. B ERMAN. & ALEX KREIT , M ARIJUANA LAW AND POLICY 48 (2020).
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There are, however, contradictory studies that suggest that cannabis has a potential for
abuse. Leigh v. Panlilio et al., suggest in their article, Screening and Evaluation of Medications
for Treating Cannabis Use Disorder, that there is a lack of attention on cannabis dependency due
to the devastating effects of other abusive drugs like opioids or nicotine. 52 Also, marijuana
dependence is often kept a secret.53 Cannabis withdrawal syndrome is classified as a mental
disorder.54 This classification highlights the fact that cannabis relapse is associated with greater
withdrawal symptoms.55 Only a subset of cannabis users will develop Cannabis Use Disorder. 56
Cannabis activates the brain chemical dopamine, which is a chemical that makes people feel
happy.57 For young people, it is possible to feel withdrawal from this dopamine hit, and such
withdrawal could lead to lower self-esteem and negative mood swings thereby creating cannabis
dependance.58
Approximately 9% of individuals that have reported using cannabis develop dependence
or addiction.59 In juxtaposition, between 8% to 12% of people who take prescription opioids
develop opioid use disorder.60 In the mid-2010s, tens of thousands of people overdosed from
heroin and other opioids.61 There are more people admitted to emergency rooms for cocaine use

52

Leigh V. Panlilio, Screening and Evaluations of Medications for Treating Cannabis Use
Disorder, I NT’L REV. NEUROBIOLOGY 87, 92 (2016).
53 Shivika Datta et al., Wonder or evil?: Multifaceted health hazards and health benefits of Cannabis sativa and its
phytochemicals, SAUDI JOURNAL OF BIOLOGICAL SCIENCES 7291, 7307 (2021).
54 Panlilio, supra note 52 at 94.
55 Id.
56 Weiss et al., supra note 41 at 46.
57 Id. at 11.
58 Datta et al. supra note 53.
59 Weiss et al. supra note 41 at 46.
60 Opioid Overdose Crisis, NATIONAL I NSTITUTE ON DRUG ABUSE (March 11, 2021), https://nida.nih.gov/drugtopics/opioids/opioid-overdosecrisis#:~:text=Between%208%20and%2012%20percent,develop%20an%20opioid%20use%20disorder.
61 M ARIJUANA LAW AND POLICY, supra note 9 at 59.

7

than any other drug.62 Opioids and cocaine, however are classified CSA Schedule II drugs while
cannabis remains on Schedule I.63
Ingestion of high doses of cannabis can produce an acute psychotic reaction, which
resolves once the intoxication wears off. 64 Studies are inconsistent when it comes to the
association between adverse mental outcomes and cannabis use. 65 While links between cannabis
and schizophrenia have been replicated, the evidence suggests that most cannabis users do not
develop schizophrenia.66
Scientists conduct rodent research to mimic periodic adolescent use of cannabis. 67 The
results of those studies indicate that adult rates with low to moderate THC exposure during
adolescence exhibit enhanced heroin self-administration.68 The researchers noted, however, that
vulnerability to THC exposure can be explained from certain high-risk genotypes.69 In other
words, individuals with certain genes may be predisposed to having addictive traits.
Medical cannabis participants report reduced use of prescription opioids in individuals
with opioid use disorder (OUD).70 These findings have prompted a push for medical cannabis for
patients with OUD, but more research needs to be conducted. 71 In sum, cannabis research
teaches that the potential for cannabis abuse is moderate when compared to other drugs,
including drugs that are lower on the federal schedule.
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The second prong of the CSA Schedule I criteria is that the drug at issue have “no
accepted medical use in treatment in the United States.” 72 This is significant because cannabis
has many known and accepted medical uses.73 As such, this prong does not apply to cannabis.
The Drug Enforcement Agency (DEA) has developed a list of five criteria that it considers when
evaluating whether a drug has an accepted medical use.74 Those factors are whether: (1) the
drug’s chemistry is known and reproducible; (2) there are adequate safety studies; (3) there are
adequate and well-controlled studies proving efficacy; (4) the drug is accepted by qualified
experts; and (5) the scientific evidence is available.
A. The Drug’s Chemistry Must be Known and Reproducible
A potential problem with satisfying first component of the five-factor test—that the
drug’s chemistry must be known and reproducible—is the difficulty with reproducing cannabis. 75
The drug’s chemical properties, however, are known and well documented. 76
A recent article published by the Multidisciplinary Publishing Institute (MPI) gives an
overview of the chemical makeup of cannabis.77 It explains that, “Cannabis sativa, a member of
herbaceous Cannabaceae family of plants, produces more than 568 unique compounds, of which
more than 100 belong to the unique class of phytocannabinoids. These are organic molecules
with a polyphenolic structure.”78 The article goes on to describe what phytocannabinoids are,
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“such as, tetrahydrocannabinol (THC), cannabidiol (CBD), tetrahydrocannabinolic acid (THCA),
and cannabidiolic acid (CBDA)”.79
The problem is that different compositions of phytocannabinoids have widely varying
ranges of biological and psychological responses. 80 An example of this variation would be that
the THC content in cannabis can range from 0.14% to more than 25% depending on the
concentration of phytocannbinoids from plant to plant. 81 Moreover, the pharmacological
responses produced by cannabis or cannabis extracts are different from those of a single
phytocannabinoid.82
A possible way to circumvent this issue is to point to the use of cannabinoids in treating
epilepsy. In June 2018, the FDA approved Epidiolex, which is a cannabidiol oral solution that
treats Lennox-Gastaut Syndrome (LGS) and Dravet syndrome (DS). 83 LGS and DS are rare
epileptic disorders.84
Epidiolex is the first FDA-approved drug that contains a purified substance derived from
cannabis.85 Well-controlled clinical studies supported Epidiolex’s approval to treat epilepsy. 86
The FDA contends that prescribers, “can have confidence in the drug’s uniform strength and
consistent delivery that appropriate dosing needed for treating patients with these complex and
serious epilepsy syndromes.”87
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Besides Epidolex, the FDA has approved three cannabis-related drug products:88 Marinol,
Syndros, Cesamet.89 These products are synthesized from cannabinoids, meaning that they are
man-made to mimic the structure of cannabis chemicals. 90 These mimics, however, do not
always produce the same effects as natural cannabis. 91 Marinol and Syndros contain dronabinol,
a synthetic delta-9-tetrahydrocannabinol (THC).92 Both drugs are used to treatment anorexia
associated with weight loss in AIDS patients. 93 Cesamet contains nabilone, which a synthetically
derived substance similar to THC.94 Cesamet treats nausea and vomiting associated with cancer
chemotherapy.95
B. There Must be Adequate Safety Studies; There Must be Adequate and Well-Controlled
Studies Proving Efficacy
These two factors in the medical use analysis are grouped together because they are
inextricably intertwined.96 The DEA has explained that, “a determination that a drug is
ineffective is tantamount to a determination that it is unsafe.” 97
Research proves that cannabis has neuroprotective properties, which means it protects
brain cells from harm.98 Studies demonstrate that cannabis can reduce the likelihood of head and
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neck cancer.99 The drug also is effective in reducing nausea, vomiting, and muscle spasms. 100
The most common conditions for which medical cannabis is used are pain, spasticity associated
with multiple sclerosis, post-traumatic stress disorder, cancer, epilepsy, cachexia, cachexia
glaucoma, HIV/AIDS, and degenerative neurological conditions. 101
The National Academies of Sciences, Engineering, and Medicine (NAS) reported
findings from thirty-seven studies assessing the efficacy for cannabis or cannabinoids. 102 The
NAS concluded that cannabis is an effective method of treatment for a number of medical
ailments.103
Congress presupposed that cannabis had no therapeutic medical uses when it placed the
drug on Schedule I in 1970.104 Ironically, classifying a drug as a Schedule I list makes
researching it potential medical uses exceedingly difficult. 105 Researchers who want to conduct
research on cannabis have to navigate a series of review processes. 106
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These processes begin with a researcher submitting an investigation new drug (IND)
application to the FDA.107 In the next step, the investigator may contact the National Institute on
Drug Abuse (NIDA), an important source of research-grader cannabis, to obtain an
administrative letter of authorization (LOA). 108 An LOA describes the manufacturer’s facilities
and the availability and relevant characteristics of the desired cannabis product. 109 These
characteristics include, strains quality, strength pharmacology, toxicology, etc.). 110 To safeguard
against the acquisition of cannabis for non-research purposes, researchers also have to apply to
the DEA for registration and site licensure before conducting any studies with cannabis or
cannabis derived substance.111 The researcher has to submit the IND and LOA to the FDA and
the DEA for review.112
After submitting the applications, the researcher must wait at least 30 days before
initiating research.113 During this time the FDA reviews the application to ensure that the
research participants will not be exposed to unreasonable risk. 114 If the FDA does determine that
the proposed research would expose study participants to unreasonable risk or that there is
another deficiency in the IND application, the research project can be put on hold. 115 The
researcher will not be to be able to continue the research project until the deficiencies are
resolved.116
In some states, researchers also have to apply for and receive a controlled substance
certificate from a state board of medical examiners or a controlled substance registration from a
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department of the state government.117 The researchers can only apply for DEA registration and
site licensure when the necessary approvals118 have been secured from the state.119
Additionally, researchers need to submit a research protocol to the DEA that includes
details regarding the security provisions for storing and dispensing the cannabis. 120 To ensure
that the cannabis will be stored and accessed in accordance with the DEA security requirements,
DEA officials may perform a preregistration inspection of the facility where the research will
take place.121 Researchers need to bear the costs of meeting these security requirements. 122
There is yet another obstacle that researchers need to overcome in order to research
cannabis, which is approval to conduct a human clinical trial. 123 The researchers need to get
approval by an institutional review board showing the board that they have an appropriate plan to
protect the rights and welfare of the human subjects. 124 If a study is being conducted in a clinical
research center, a separate review may be required by this entity’s medical or research advisory
committee.125
These substantial layers of bureaucracy that emerge from trying to research a Schedule I
substance have discouraged a number of cannabis researchers from apply for grant funding or
pursuing additional research efforts.126
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As a result, and although the NAS reported that cannabis’s effectiveness in treatment for
certain conditions was backed my “substantial evidence,” cannabis’s efficacy regarding the vast
majority of the medical conditions discussed is suffered from “insufficient or no evidence upon
which to base conclusion about therapeutic effects.” 127 Consequently. the NAS stressed the need
for more substantial research to provide comprehensive and conclusive evidence on the
therapeutic effects of cannabis and cannabinoids. 128
The NAS is not the only scientific enterprise that has called for more additional
marijuana research. The Institute of Medicine published a report demanding more rigorous and
systematic research into the potential medical benefits of cannabis. 129 Leading medical
organizations, including the American Medical Association and the American Cancer Society,
also have advocated for more research into the potential benefits of cannabis. 130
Cannabis’s classification as a Schedule I drug, in conjunction with the numerous unique
federal rules regulating cannabis research, have long precluded large-scale scientific research as
to the drug’s therapeutic effects in the United States. 131 Scholars contend that rescheduling
cannabis to at least Schedule II would make it possible for large pharmaceutical companies to
conduct research on cannabis, including clinical trial.132 It is possible for researchers to apply to
the FDA and DEA for access to drugs on the Schedule I drugs. 133 The problem is that researchers
must obtain the cannabis they study from a single federal facility created to legally cultivate
cannabis for research studies134 at the University of Mississippi.135 Researchers argue that this
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limitation on cannabis supply has dramatically impeded legitimate research in the United
States.136
In May 2021, the DEA announced that it is in the process of registering several additional
American companies to produce cannabis for medical and scientific research. 137 Scientists will
nonetheless continue to be proscribed under federal law, a notoriously slow process138 , from
simply using the cannabis available at state-license dispensaries for their research. 139
Dr. Lyle Craker, a prominent plant biologist, applied to grow cannabis for research
purposes, and his application languished for years without approval. 140 He had to engage in a
long court battle with the DEA in order to obtain the license. Another researcher, Dr. Sue Sisley,
also received preliminary DEA approval to grow cannabis. 141 Dr. Sisley has observed that there
are many varieties of cannabis that produce different clinical effects, and that variety is not
available from the government supply of cannabis. 142
The lone facility authorized to produce cannabis for research in Mississippi also has
failed to produce a quality product. That cannabis has been d escribed as “anemic” green powder
that is very diluted.143 Researchers do not have access to cannabis with varying concentrations of
CBD and THC, or in different forms, like edibles and oils. 144 This is important because it means
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that the research conducted on cannabis in the United States often does not translate to the kind
of cannabis products that are used in the real world. 145 Scholars suggests that the biggest leap
forward for research would be the down scheduling of cannabis from Schedule I. 146
In fact, the United States House of Representatives recently passed bipartisan legislation,
the Medical Marijuana Research Act, to permit scientists to access cannabis from state-legal
dispensaries.147 This Act removes barriers for researchers approved to study cannabis.148 It sets
clear deadlines for when federal agencies need to act on research applications and makes it easier
for scientists to modify their research protocols without having to seek federal approval. 149
Proponents of the Act on both sides of the political aisle contend that its provisions will advance
our understanding of the medical benefits of cannabis. 150
There is also bipartisan agreement that the DEA has inhibited cannabis research through
its inefficient application process.151 As a result, the House Act mandates that the DEA license
more growers and eliminates any restrictions on the number of additional entities that the DEA
can registered to cultivate cannabis for research purposes. 152 It also eases the registration
process.153
The Act further delegates to HHS and the AG the creation of rules to process facilitations
between marijuana manufacturers and researchers. 154 It also requires HHS to submit a report to
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Congress within five years that assesses new research so that Congress can determine whether to
reschedule cannabis rescheduling.155 Federal prohibition continues to pose research obstacles but
this Act promises to make the process much easier going forward. 156
The Senate has passed similar legislation called the Cannabidiol and Marihuana Research
Expansion Act.157 The major difference between the House and Senate Bills is that the House
Bill allows researchers to obtain cannabis from state-legal dispensaries whereas the Senate Bill
continues to require researcher to obtain cannabis from the sole federally authorized facility (the
University of Mississippi).158
In terms of safety, the FDA-approved drug Epidiolex, which is discussed above, has
shown the consistent and safe reproduction of a product using a chemical derived from
cannabis.159 Studies also indicate that cannabis is safe and effective therapeutic but there is a
significant need for additional research. Even assuming the House and Senate reconcile their
competing bills and enact a new cannabis research law, cannabis’s ongoing classification as a
Schedule I drug will continue to inhibit scientific research. 160
C. The Drug Must be Accepted by Qualified Experts.
Besides FDA’s approval of Epidiolex, there is a swath of evidence that cannabis is
accepted by qualified experts as a viable therapeutic. One need look no further than the medical
marijuana legalization states to find that evidence. 161 States with active medical cannabis laws
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(MCLs) have seen opioid prescriptions drop nearly 20% compared to prohibition states. 162
Columbia University’s Irving Medical Center lead a research project analyzing the correlation
between medical marijuana and opioid prescriptions. 163 The research data they collected showed
that, “State MCLs were associated with a statistically significant reduction in aggregate opioid
prescribing of 144,000 daily doses (19.7% reduction) annually.” 164 Most state medical marijuana
programs require a physician’s recommendation. 165 Given the sheer number of Americans that
have obtained such recommendations, its near impossible to contend that qualified federal and
state experts have not accepted cannabis as a therapeutic. 166
D. The Scientific Evidence Must be Widely Available
The third prong of the Schedule I criteria is that a drug “lack . . . accepted safety for use .
. . under medical supervision.”167 This factor only applies to drugs that do not have new drug
application (NDA) approval.168 “NDA-approval” means a drug that has been approved by the
FDA.169 Arguably, the FDA’s approval of Epidiolex, whose active ingredient is a nonsynthesized cannabis derived chemical, means that at least one natural cannabinoid is NDA
approved. Thus, the FDA has made it widely known, through its approval, that there is scientific
evidence of cannabis’s safety.170
However, long before the FDA approval of Epidiolex, medical officials felt confident
enough in the scientific evidence of cannabis’s medical use that they would recommend their
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patients take it under the relevant circumstances.171 State medical marijuana regimes follow what
is known as the prescription/recommendation dichotomy.172 This dichotomy involves a physician
giving a recommendation to a patient, rather than a prescription, to obtain medical marijuana. 173
The physician gives the recommendation knowing full well that the patient will use the
recommendation as a means of obtaining marijuana, which is still illegal under federal law, but is
distinguished from a formal prescription.174 The distinction, in a recommendation vs. a
prescription, was relied on heavily in the Ninth Circuit case, Conant v. Walters.175
In Walters, the court enjoined the federal government from either revoking a physician’s
license to prescribe controlled substances or conducting an investigation of a physician that
might lead to such a revocation where the basis for the government’s action was solely the
physician’s professional “recommendation” to use medical cannabis. 176 The Walters court was
careful to distinguish between a physician’s treatment recommendation and physician
prescribing.177 Walters is clearly protective of doctors who recommend cannabis to their patients.
The case leaves open the possibility, however, that a physician who actually prescribed cannabis
to a patient may well be in violation of federal law.178
Since Walters, no serious effort has been made by federal authorities to prosecute
doctors.179 There are currently thirty states that have medical marijuana programs. 180 Each state
has its own unique laws defining who can access medical marijuana. 181 These laws typically
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include some list or criteria of medical conditions eligible for the state’s med ical marijuana
program.182
III. Cannabis as a Schedule III Drug
Schedule III drugs must satisfy the following criteria: (1) they must have a potential for
abuse less than other substances in schedules I and II; (2) they must have a currently accepted
medical use in treatment in the U.S.; and (3) their abuse may lead to moderate or low physical
dependence or high psychological dependence. 183
Cannabis satisfies the first component here because it has a lower potential of abuse than
several Schedule I and II drugs, including heroin, cocaine, and methamphetamine. 184 It also
meets the second component for several reasons.
First, the drugs chemistry is known and reproducible, as the chemical makeup for
cannabis is well documented 185 , and the cannabis-derived drug Epidiolex can be successfully
reproduced.186
Second, there has been adequate safety studies and adequate well-controlled studies
proving the efficacy of cannabis.187 Studies prove that cannabis has neuroprotective properties188 ,
has the potential to reduce the likelihood of head and neck cancer189 , and can effectively reduce
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nausea, vomiting, and muscle spasms.190 The NAS has concluded, after assessing thirty-seven
studies, that cannabis is an effective method of treatment for a number of medical ailments.191
Third, the drug is accepted by qualified experts. 192 Again, the FDA has approved a
cannabis-derived drug and has noted the safety of its use. 193 Additionally, most state medical
marijuana programs require a physician’s recommendation194 , and there have been a substantial
number of Americans who have obtained these recommendations, signifying the federal and
state acceptance of cannabis as a therapeutic. 195
Fourth, the scientific evidence is widely available. 196 The FDA has made the evidence of
cannabis medicinal use widely available by approving Epidiolex. 197 Also, in the last 20 years
there has been no serious efforts from federal authorities to prosecute doctors in the thirty states
that have medical marijuana programs, an implicit acceptance of the scientific evidence of
cannabis efficacy.198
Cannabis also satisfies the third component because there is a chance that cannabis leads
to moderate physical dependence and possible psychological dependence in a small group of
people.199
IV. The Marijuana Opportunity Reinvestment and Expungement Act (MORE)
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The MORE Act, which has been introduced in both chambers of Congress, removes
cannabis from list of federally banned drugs under the CSA. 200 It also includes provisions about
prison sentences, criminal reform, taxes on cannabis, and legalization on the state level. 201 The
House of Representatives recently passed the MORE Act and it is currently pending in the
Senate.202 If the Senate passes the Act and the President signs it into law, there will be no need to
down schedule cannabis to Schedule III because it will be entirely d e-scheduled and the
objectives of this paper will be fulfilled.
V. Proposal
This paper is certainly not the first to propose the down scheduling of cannabis, and it
likely will not be the last. Advocates have fought for the rescheduling cannabis through many
different means over the last five decades. In the 1973 case, United States v. LaFroscia,203 a
defendant brought the first constitutional challenge to the scheduling of cannabis. 204 There, the
court refused to address the defendant’s rescheduling claim because he had not exhausted
administrative procedures that Congress established to challenge a scheduling determination. 205
Even when advocates have used the correct administrative procedures to challenging the
scheduling of cannabis, they have failed. The National Organization for the Reform of Marijuana
Laws (NORML) filed a rule-making petition in 1972 with the U.S. Court of Appeals for the D.C.
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Circuit requesting that cannabis be removed from the CSA entirely or transferred to Schedule V.
The court, however, rejected the petition. 206
On remand, the court found that the placement of cannabis on Schedule I did not only
flow from the lack of currently accepted medical uses, but required the balancing of possible
medical uses with the potential for abuse.207 The court did acknowledge that there were possible
treatment uses for cannabis and that further studies should be conducted. 208 The court remanded
the case again for further findings with the Secretary of Health, Education, and Welfare
(HEW).209 After a long delay HEW recommended that cannabis remain on the Schedule I drug
list and the DEA denied NORML’s petition to reschedule cannabis. 210
NORML then filed a third request with the U.S. Court of Appeals, and the court, in turn,
ordered the DEA to review the petition in its entirety. 211 In the mid-1980s the DEA called for
public hearing on cannabis’s proper classification. 212 The administrative judge ruled that
cannabis should be transferred from Schedule I to Schedule II, based on the evidence of a small
group of respective physicians that accepted the medical use of cannabis. 213 However, based on
an eight-factor test the DEA Administrator rejected this recommendation requiring a greater
showing to prove currently accepted medical use before approving such a rescheduling. 214
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This rejection was challenged by the Alliance for Cannabis Therapeutics (ACT) and
NORML together.215 After showing evidence that that the DEA Administrator unreasonably
rejected the petition, the court remanded the petition to the Administrator. 216 The Administrator,
again, upheld the rejection of the petition.217 This rejection was appealed by the NORML to the
D.C. Circuit court, who also upheld the Administrator’s objection, but established a new fivepart test to determine whether a substance has a currently accepted medical use. 218 The five-part
test was analyzed in the medical use analysis of this paper. The new test was, interestingly,
focused on adequate controlled studies to determine efficacy and safety of cannabis. 219 In sum,
the DEA has fought fervently to stop the rescheduling of cannabis.220
Annaliese Smith’s law review comment, Marijuana as a Schedule I Substance: Political
Ploy or Accepted Science?, also makes the argument that cannabis should classified as a
Schedule III drug.221 Smith’s comment points out the mistakes made by prior petitioners who
have sought to have cannabis down scheduled: the failure to present sufficient evidence to
establish that cannabis does not have a high potential for abuse and has known and accepted
medical uses.222
This paper also aims to further that goal, and, in order to avoid past petitioning mistakes,
it is important to be clear about why cannabis ought to be moved to Schedule III. It is also
important to note the difficulty in establishing sufficient evidence of cannabis’s medical uses due
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to the drug’s placement on Schedule I. Through the rescheduling regulations, the DEA is
essentially asking for us to open a locked box, and the key is in the box.
The DEA can, and must, reschedule cannabis to Schedule III. Moving cannabis to
Schedule III will open up important research opportunities. This is particularly critical should the
MORE Act not get enacted. That stated, the Cannabidiol and Marihuana Expansion Act, and the
Medical Marijuana Research Act, demonstrate that there is near unanimous support in Congress
that more research needs to be done into cannabis for medical purposes.223
Rescheduling cannabis is the first step to full federal legalization and will facilitate the
short-term goal of making cannabis more readily available for research purposes. Congress
should amend, or enact legislation similar to, the Cannabidiol and Marihuana Expansion Act and
the Medical Marijuana Research Act, that mandates that the DEA and FDA approve two federal
facilities in every state to manufacture cannabis for research purposes. The bill also should
stipulate that these facilities need to make quality grade medical marijuana with the chemical
components of THC and CBD that are common to Cannabis Sativa rather than hemp. 224 It should
further ensure that there are variety of different cannabis strains available so researchers can test
how different chemical combinations react with the human body.
There should also be a shift in regulatory power from the DEA to the FDA when it comes
to scheduling decisions. The DEA is a law enforcement agency225 that has always aired on the
side of caution when it comes to scheduling decisions, evidenced by the fact that it has never
down-scheduled any controlled substance.226 The DEA has also aggressively fought against the
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rescheduling of cannabis despite evidence of medical use.227 In juxtaposition the FDA is a
scientific public health agency228 that has recently approved four cannabis drug applications, and
has seriously considered the medical uses of cannabis as they relate to the tenants of the CSA.229
The FDA should have authority over rescheduling decisions as well as applications for growing
facilities. The FDA should be a given a time constraint on responses to grower applications, to
avoid the pervading issue of delayed applications.
VI. Conclusion
Under the DEA’s own guidelines, cannabis ought to be removed from Schedule I. It has known
and accepted medical uses and there is accepted safety for use of cannabis under medical
supervision. The drug also does not have a high potential for abuse. The first step to federal
legalization is to down-schedule cannabis to Schedule III so that more research can be conducted
concerning the drug’s therapeutic uses. In the alternative, or in conjunction with this proposal,
Congress needs to shift power from the DEA to the FDA to analyze the medical viability of
Schedule I drugs, as the DEA has only acted in their policing capacity while ignoring the tide of
mounting evidence surrounding the medical viability of cannabis.
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